← Leaderboards
Roberta Anderson Ballard
Children'S Hospital Of Philadelphia
$14,822,665
Attributed
$14,822,665
Total exposure
11
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2005–13$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$14,822,665 · 11
By mechanism
U01$14,087,200 · 2
M01$452,332 · 8
P50$283,133 · 1
Top collaborators
No co-investigators on record.
Most similar at Children'S Hospital Of Philadelphia
Same institution · by research overlap
- Tamim H Shaikh$5,205,747
- Pinchas Cohen$25,721,568
- Beverly Banks$560
Others in their field
Top investigators on “Inflammation”
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$89,523,713
- David Heimbrook · Leidos Biomedical Research, Inc.$85,243,263
- Randall J Bateman · Washington University$64,707,456
- Peter Scott Heeger · Case Western Reserve University$56,547,884
Research focus
InflammationNitric OxideClinical ResearchHuman SubjectBronchopulmonary DysplasiaPremature Infant HumanClinical TrialsBiomarkerOxidative StressRespiratory Disorder ChemotherapyRespiratory TherapyHuman Therapy EvaluationPulmonary SurfactantsChemopreventionRespiratorsLung InjuryCytokineDrug Screening /EvaluationTissue Resource /RegistryBiochemicalBaseAlveolarAsthmaCaffeine
Grant awards (22)
Trial of Late SURFactant (TOLSURF) to Prevent BPD - Clinical Coord Ctr$952,443
U01 · FY2013 · HL · contact PI
Trial of Late SURFactant (TOLSURF) to Prevent BPD - Clinical Coord Ctr$1,383,645
U01 · FY2012 · HL · contact PI
Trial of Late SURFactant (TOLSURF) to Prevent BPD - Clinical Coord Ctr$1,626,614
U01 · FY2011 · HL · contact PI
Trial of Late SURFactant (TOLSURF) to Prevent BPD - Clinical Coord Ctr$1,604,244
U01 · FY2010 · HL · contact PI
Trial of Late SURFactant (TOLSURF) to Prevent BPD - Clinical Coord Ctr$1,787,395
U01 · FY2009 · HL · contact PI
CORE--CLINICAL$283,133
P50 · FY2005 · HL
PATHOBIOLOGY OF BRONCHOPULMONARY DYSPLASIA$35,672
M01 · FY2005 · RR
LOW DOSE INO IN CHRONIC LUNG DISEASE IN PRETERM INFANT$32,318
M01 · FY2005 · RR
LOW DOSE INO IN CHRONIC LUNG DISEASE IN PRETERM INFANT$23,996
M01 · FY2005 · RR
PATHOBIOLOGY OF BRONCHOPULMONARY DYSPLASIA$1,097
M01 · FY2005 · RR
Low dose INO in chronic lung disease in preterm infant$105,123
M01 · FY2004 · RR
Pathobiology of bronchopulmonary dysplasia$30,959
M01 · FY2004 · RR
Low dose INO in chronic lung disease in preterm infant$21,869
M01 · FY2004 · RR
Pathobiology of bronchopulmonary dysplasia$14,053
M01 · FY2004 · RR
INHALED NO IN PREVENTION OF CHRONIC LUNG DISEASE$1,604,333
U01 · FY2003 · HL
INHALED NO IN PREVENTION OF CHRONIC LUNG DISEASE$1,839,151
U01 · FY2002 · HL
PATHOBIOLOGY OF BRONCHOPULMONARY DYSPLASIA$186,685
M01 · FY2002 · RR
NITRIC OXIDE FOR CHRONIC LUNG DISEASE IN PRETERM INFANT$0
M01 · FY2002 · RR
INHALED NO IN PREVENTION OF CHRONIC LUNG DISEASE$1,741,773
U01 · FY2001 · HL
INHALED NO IN PREVENTION OF CHRONIC LUNG DISEASE$1,547,602
U01 · FY2000 · HL
PATHOBIOLOGY OF BRONCHOPULMONARY DYSPLASIA$560
M01 · FY2000 · RR
NITRIC OXIDE FOR CHRONIC LUNG DISEASE IN PRETERM INFANT$0
M01 · FY2000 · RR